These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 30107620

  • 1. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A, Jost WH.
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [Abstract] [Full Text] [Related]

  • 2. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
    Antonini A, Nitu B.
    J Neural Transm (Vienna); 2018 Aug; 125(8):1131-1135. PubMed ID: 30006821
    [Abstract] [Full Text] [Related]

  • 3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004 Aug; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 4. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A, Nagy H, Radics P, Tóth A, Tamás G.
    Ideggyogy Sz; 2013 Nov 30; 66(11-12):365-71. PubMed ID: 24555235
    [Abstract] [Full Text] [Related]

  • 5. On demand therapy for Parkinson's disease patients: Opportunities and choices.
    Hauser RA, LeWitt PA, Comella CL.
    Postgrad Med; 2021 Sep 30; 133(7):721-727. PubMed ID: 34082655
    [Abstract] [Full Text] [Related]

  • 6. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE, Dollenz C, Soliveri P, Albanese A.
    Eur J Neurol; 2012 Jan 30; 19(1):76-83. PubMed ID: 21645174
    [Abstract] [Full Text] [Related]

  • 7. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA, Luquin MR, Vaamonde J, Grandas F, Martinez Lage JM.
    Can J Neurol Sci; 1987 Aug 30; 14(3 Suppl):488-92. PubMed ID: 3676922
    [Abstract] [Full Text] [Related]

  • 8. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1996 Jun 30; 60(6):634-7. PubMed ID: 8648329
    [Abstract] [Full Text] [Related]

  • 9. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
    Clarke CE, Worth P, Grosset D, Stewart D.
    Parkinsonism Relat Disord; 2009 Dec 30; 15(10):728-41. PubMed ID: 19805000
    [Abstract] [Full Text] [Related]

  • 10. Use of apomorphine in Parkinson's disease.
    Stocchi F.
    Neurol Sci; 2008 Dec 30; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [Abstract] [Full Text] [Related]

  • 11. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W.
    Neurology; 2009 Feb 17; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [Abstract] [Full Text] [Related]

  • 12. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
    Melamed E, Zoldan J, Galili-Mosberg R, Ziv I, Djaldetti R.
    J Neural Transm Suppl; 1999 Feb 17; 56():173-83. PubMed ID: 10370911
    [Abstract] [Full Text] [Related]

  • 13. Medical and surgical management of advanced Parkinson's disease.
    Antonini A, Moro E, Godeiro C, Reichmann H.
    Mov Disord; 2018 Jul 17; 33(6):900-908. PubMed ID: 29570862
    [Abstract] [Full Text] [Related]

  • 14. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
    Santos-García D, Macías M, Llaneza M, Fuster-Sanjurjo L, Echarri-Piudo A, Belmonte S, Blanco S.
    Neurologia; 2010 Jul 17; 25(9):536-43. PubMed ID: 21093702
    [Abstract] [Full Text] [Related]

  • 15. [Device-aided therapies in advanced Parkinson's disease].
    Timofeeva AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016 Jul 17; 116(12):54-60. PubMed ID: 28139627
    [Abstract] [Full Text] [Related]

  • 16. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK, Bösch S, Luginger E, Wagner M, Poewe W.
    Adv Neurol; 1999 Jul 17; 80():545-8. PubMed ID: 10410769
    [No Abstract] [Full Text] [Related]

  • 17. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ, Turner K, Lees AJ.
    Mov Disord; 2002 Nov 17; 17(6):1235-41. PubMed ID: 12465062
    [Abstract] [Full Text] [Related]

  • 18. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
    Castaño B, Mateo D, Giménez-Roldán S.
    Neurologia; 2007 Apr 17; 22(3):133-7. PubMed ID: 17364250
    [Abstract] [Full Text] [Related]

  • 19. Use of advanced therapies for Parkinson's disease in Norway.
    Ezat B, Pihlstrøm L, Aasly J, Tysnes OB, Egge A, Dietrichs E.
    Tidsskr Nor Laegeforen; 2017 May 17; 137(9):619-623. PubMed ID: 28468476
    [Abstract] [Full Text] [Related]

  • 20. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV, Katunina EA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013 May 17; 113(12):105-12. PubMed ID: 24596973
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.